

Supplemental Table 2: Frequencies of MDSCs (n=133) and Tregs (n=123) according to type and time-point of prior systemic treatments (combined cohorts)

	Prior therapy n (%)	MDSCs - mean % frequency (n)						Tregs - mean % frequency (n)					
		Prior therapy	No prior therapy	p	Within 4 weeks ^a	Not within 4 weeks ^a	p	Prior therapy	No prior therapy	p	Within 4 weeks ^a	Not within 4 weeks ^a	p
Any prior systemic therapy	99 (74.4%)	12.9 (99)	14.2 (34)	0.375	13.8 (39)	12.9 (88) ^b	0.572	7.6 (93)	6.7 (39)	0.197	7.9 (36)	7.0 (81) ^b	0.140
IL-2	7 (5.3%)	10.9 (7)	13.4 (127)	0.422	15.8 (3)	13.2 (130)	0.643	9.5 (6)	7.3 (117)	0.225	13.9 (2)	7.3 (121)	<0.001
Anti-CTLA4	12 (9.0%)	10.1 (12)	13.6 (121)	0.143	9.6 (5)	13.4 (128)	0.404	7.9 (12)	7.3 (111)	0.490	7.6 (5)	7.4 (118)	0.842
IFN-α	46 (34.6%)	12.4 (46)	13.7 (87)	0.338	25.3 (1)	13.1 (131) ^b	Na	6.9 (45)	7.7 (78)	0.138	9.8 (1)	7.4 (121) ^b	Na
Immunotherapy other than IL-2, anti-CTLA4 or IFN-α	19 (14.3%)	13.0 (19)	13.3 (114)	0.892	13.6 (6)	13.3 (126) ^b	0.942	8.2 (19)	7.2 (104)	0.217	8.9 (6)	7.3 (116) ^b	0.393
BRAF or MEK-Inhibitor	19 (14.3%)	13.1 (19)	13.3 (114)	0.915	14.6 (10)	13.2 (122) ^b	0.683	7.8 (15)	7.3 (108)	0.512	7.6 (8)	7.4 (114) ^b	0.817
Any other systemic therapy (e.g. chemotherapy)	43 (32.3%)	13.0 (43)	13.4 (90)	0.741	12.8 (16)	13.3 (114) ^b	0.813	8.1 (43)	7.0 (80)	0.064	7.4 (16)	7.3 (104) ^b	0.862

MDSCs – myeloid-derived suppressor cells; Tregs – regulatory T cells, IL-2 – interleukin-2; IFN-α – interferon-α. Na – not available; ^a last administration of the treatment was applied within four weeks before blood draw for this study; ^b - the exact date of last administration of systemic treatment could not be clarified for 6/133 patients. These patients were not considered in the indicated analysis